BR112022017891A2 - Métodos para tratar a infecção por coronavírus e lesão pulmonar induzida por inflamação resultante - Google Patents

Métodos para tratar a infecção por coronavírus e lesão pulmonar induzida por inflamação resultante

Info

Publication number
BR112022017891A2
BR112022017891A2 BR112022017891A BR112022017891A BR112022017891A2 BR 112022017891 A2 BR112022017891 A2 BR 112022017891A2 BR 112022017891 A BR112022017891 A BR 112022017891A BR 112022017891 A BR112022017891 A BR 112022017891A BR 112022017891 A2 BR112022017891 A2 BR 112022017891A2
Authority
BR
Brazil
Prior art keywords
methods
lung injury
induced lung
coronavirus infection
resulting inflammation
Prior art date
Application number
BR112022017891A
Other languages
English (en)
Inventor
Durrant Cameron
Chappell Dale
Original Assignee
Humanigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humanigen Inc filed Critical Humanigen Inc
Publication of BR112022017891A2 publication Critical patent/BR112022017891A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

MÉTODOS PARA TRATAR A INFECÇÃO POR CORONAVÍRUS E LESÃO PULMONAR INDUZIDA POR INFLAMAÇÃO RESULTANTE. A presente invenção fornece métodos para tratar um indivíduo infectado com coronavírus 2019 (SARS-CoV-2) compreendendo administrar ao indivíduo uma quantidade terapeuticamente eficaz de um antagonista de GM-CSF ou uma quantidade terapeuticamente eficaz de um antagonista de GM-CSF e um segundo fármaco, incluindo um agente antiviral, uma vacina anti-SARS-CoV-2 e soro contendo anticorpos policlonais humanos para SARS-CoV-2.
BR112022017891A 2020-03-08 2021-03-08 Métodos para tratar a infecção por coronavírus e lesão pulmonar induzida por inflamação resultante BR112022017891A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062986751P 2020-03-08 2020-03-08
US202063027128P 2020-05-19 2020-05-19
US202063072716P 2020-08-31 2020-08-31
US202063088971P 2020-10-07 2020-10-07
PCT/US2021/021402 WO2021183456A1 (en) 2020-03-08 2021-03-08 Methods for treating coronavirus infection and resulting inflammation-induced lung injury

Publications (1)

Publication Number Publication Date
BR112022017891A2 true BR112022017891A2 (pt) 2022-11-01

Family

ID=77670820

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017891A BR112022017891A2 (pt) 2020-03-08 2021-03-08 Métodos para tratar a infecção por coronavírus e lesão pulmonar induzida por inflamação resultante

Country Status (11)

Country Link
US (1) US20210309733A1 (pt)
EP (1) EP4118115A4 (pt)
JP (1) JP2023520979A (pt)
KR (1) KR20230005139A (pt)
CN (1) CN115605508A (pt)
AU (1) AU2021235899A1 (pt)
BR (1) BR112022017891A2 (pt)
CA (1) CA3173970A1 (pt)
IL (1) IL296082A (pt)
MX (1) MX2022011111A (pt)
WO (1) WO2021183456A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210284744A1 (en) 2020-03-15 2021-09-16 Kiniksa Pharmaceuticals, Ltd. Treatment of cytokine release syndrome with gm-csf antagonists
WO2022192093A1 (en) * 2021-03-08 2022-09-15 Humanigen, Inc. Methods for treating coronavirus infection and resulting inflammation-induced lung injury
WO2023069461A2 (en) * 2021-10-19 2023-04-27 Vaxxinity, Inc. Method for the prevention and treatment of coronavirus disease
WO2023076096A1 (en) * 2021-10-27 2023-05-04 Rush University Medical Center Methods of treating the effects of cytokine storms
RU2769223C1 (ru) * 2021-12-22 2022-03-29 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Средство и способ терапии и экстренной профилактики заболеваний, вызываемых вирусом SARS-CoV-2 на основе рекомбинантного антитела и гуманизированного моноклонального антитела
RU2765731C1 (ru) * 2021-12-22 2022-02-02 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Гуманизированное моноклональное антитело, специфически связывающиеся с RBD S белка вируса SARS-CoV-2, средство и способ для терапии и экстренной профилактики заболеваний, вызываемых вирусом SARS-CoV-2
CN114150005B (zh) * 2022-02-09 2022-04-22 广州恩宝生物医药科技有限公司 用于预防SARS-CoV-2奥密克戎株的腺病毒载体疫苗
WO2023177995A2 (en) * 2022-03-18 2023-09-21 Ohio State Innovation Foundation Cdp-choline a host-directed therapeutic for disease caused by sars cov-2 infection
WO2023215478A1 (en) * 2022-05-05 2023-11-09 Theravance Biopharma R&D Ip, Llc Nezulcitinib for delivery by nebulized oral inhalation
WO2023239197A1 (ko) * 2022-06-09 2023-12-14 주식회사 자이메디 면역 증진 활성이 있는 신규 crs 단편 펩타이드 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007323541B2 (en) * 2006-11-21 2012-01-19 Kalobios Pharmaceuticals, Inc. Methods of treating chronic inflammatory diseases using a GM-CSF antagonist
US8609101B2 (en) * 2009-04-23 2013-12-17 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies
EP2968517A4 (en) * 2013-03-15 2017-02-22 Bullet Biotechnology, Inc. Specific multivalent virus-like particle vaccines and uses thereof
BR112017023425A2 (pt) * 2015-04-29 2018-07-24 Foresight Biotherapeutics Inc combinações terapêuticas de terapias antivirais e anti-inflamatórias
WO2018013918A2 (en) * 2016-07-15 2018-01-18 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
FR3057773B1 (fr) * 2016-10-21 2020-06-19 Universite Claude Bernard Lyon 1 Nouvelles compositions antivirales pour le traitement des infections liees aux coronavirus
EP3691663A4 (en) * 2017-10-02 2021-08-18 Humanigen, Inc. METHOD OF TREATING IMMUNOTHERAPY ASSOCIATED TOXICITY USING GM-CSF ANTAGONIST
EP3697404A4 (en) * 2017-10-18 2021-07-21 Versitech Limited COMPOSITIONS AND METHODS FOR BROAD SPECTRUM ANTIVIRAL THERAPY
US11655293B2 (en) * 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
AU2020289560A1 (en) * 2019-06-05 2021-12-23 Emory University Peptidomimetics for the treatment of coronavirus and picornavirus infections
US10973908B1 (en) * 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Also Published As

Publication number Publication date
EP4118115A1 (en) 2023-01-18
CA3173970A1 (en) 2021-09-16
CN115605508A (zh) 2023-01-13
IL296082A (en) 2022-11-01
EP4118115A4 (en) 2024-04-17
US20210309733A1 (en) 2021-10-07
AU2021235899A1 (en) 2022-10-13
JP2023520979A (ja) 2023-05-23
KR20230005139A (ko) 2023-01-09
WO2021183456A1 (en) 2021-09-16
MX2022011111A (es) 2023-03-02

Similar Documents

Publication Publication Date Title
BR112022017891A2 (pt) Métodos para tratar a infecção por coronavírus e lesão pulmonar induzida por inflamação resultante
CY1118059T1 (el) Συνθεσεις αντιλοιμωδων βασει λιπιδιων για αγωγη πνευμονικων λοιμωξεων
BR112022016413A2 (pt) Método para o tratamento ou prevenção do coronavírus causado pelo vírus coronavírus da síndrome respiratória aguda grave 2, composto, e, uso de um composto
BR112022018236A2 (pt) Compostos antivirais e métodos para a sua administração
NZ597082A (en) Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
BR0210804A (pt) Vacinação de dose única com mycoplásma hyopneumoniae
BR0316685A (pt) Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade
BR0011343A (pt) Dispositivo de distribuição de medicamento,e,métodos de administrar um medicamento por inalação,e de,tratamento de um paciente com distúrbio respiratório
BR0111366A (pt) Vacina de poxvìrus recombinante do vìrus da sìndrome respiratória e reprodutiva de porcino (prrsv)
BR112022010798A2 (pt) Derivado de metileno-naftaleno-éter de fenilisoxazolila, seu uso e composição farmacêutica compreendendo o mesmo
Weiland et al. Clinical evaluation of intranasal medetomidine–ketamine and medetomidine–S (+)-ketamine for induction of anaesthesia in rabbits in two centres with two different administration techniques
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112022016507A2 (pt) Vacinas contra o coronavírus e métodos de uso
BR112012020185A2 (pt) uso de preparações de heparina oral para tratar doenças e afecções do trato urinário.
MX2021010834A (es) Compuesto y metodo para la prevencion de transmision del virus de influenza.
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
BR112022022378A2 (pt) Métodos para tratamento da doença de crohn com anticorpo específico anti-il23
MX2020010977A (es) Procedimientos de tratamiento de infecciones fúngicas.
Schulte et al. SARS-CoV-2 vaccination in multiple sclerosis: A clearer picture for the time point during CD20 depleting therapy
AU2013240456B2 (en) Administration of eritoran or pharmaceutically acceptable salts thereof to treat orthomyxovirus infections
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
BR112022024999A2 (pt) Inibidor tlr7 em combinação com prednisolona ou hidroxicloroquina para o tratamento do lúpus eritematoso cutâneo
WO2014193269A3 (ru) Лекарственное средство на основе дииндолилметана и его применение для лечения гриппа и респираторных вирусных инфекций
BR112018072177A2 (pt) composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta
BR112022018160A2 (pt) Método de produção de composição de soro para prevenir ou tratar doenças infecciosas relacionadas à mucosa em mamíferos jovens, composição de soro produzida por ele, e uso da mesma

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing